Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 3,577 Cr.
- Current Price ₹ 777
- High / Low ₹ 832 / 435
- Stock P/E 41.1
- Book Value ₹ 177
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 177 to 114 days.
Cons
- Stock is trading at 4.39 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 21.7 days to 88.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 14 | 35 | 215 | 398 | 517 | |
| 12 | 23 | 173 | 309 | 388 | |
| Operating Profit | 2 | 13 | 42 | 90 | 129 |
| OPM % | 14% | 36% | 19% | 23% | 25% |
| 0 | 4 | 3 | 19 | 26 | |
| Interest | 1 | 2 | 9 | 22 | 23 |
| Depreciation | 1 | 2 | 10 | 17 | 24 |
| Profit before tax | 1 | 12 | 25 | 71 | 108 |
| Tax % | 13% | 32% | -31% | 17% | |
| 1 | 8 | 33 | 58 | 86 | |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 18.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 204% |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 290% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 768 |
| 15 | 63 | 258 | 315 | 241 | |
| 8 | 23 | 160 | 126 | 233 | |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,288 |
| 7 | 27 | 235 | 301 | 540 | |
| CWIP | 8 | 34 | 97 | 172 | 16 |
| Investments | 15 | 16 | 0 | 0 | 2 |
| 29 | 53 | 289 | 754 | 731 | |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,288 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -10 | -1 | -26 | -46 | |
| -24 | -48 | -54 | -429 | |
| 36 | 46 | 87 | 573 | |
| Net Cash Flow | 2 | -3 | 8 | 98 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 |
| Inventory Days | 135 | 89 | 184 | 232 |
| Days Payable | 324 | 388 | 556 | 275 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 |
| Working Capital Days | 359 | -7 | -16 | 88 |
| ROCE % | 18% | 12% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Non-Deal Roadshow on 11 December 2025 in Pune hosted by Elara Capital (physical).
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Philippine FDA approved 10 products (cardio/CNS/pain); Philippines market opportunity US$23M (Dec 5, 2025).
-
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
1d - Renosen pledged 400,000 Senores Pharmaceuticals equity shares; disclosure dated December 04, 2025.
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 1d
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Nov - Senores Pharmaceuticals Limited has informed regarding the transcript of Earnings Conference Call held on Thursday, November 06, 2025 for Q2 & H1FY26
Concalls
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.